Recent Updates
Recently added Catalysts
BCDA Positive Sentiment

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Tuesday, May 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BioCardia, Inc. will participate in a virtual fireside chat at the A.G.P. Healthcare Company Showcase on May 20, 2026, at 11:40 AM ET. The company is known for its innovative cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases. Investors can register to attend the event and learn more about BioCardia's advancements.
Price reaction · baseline $0.9001 (2026-05-18 close) · hit after-hours · 1 other BCDA headline(s) in the window, move may be shared
day 0 close
+5.6%
day 1
+2.2%
day 3 · peak
+6.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • BioCardia is recognized as a leader in cellular therapeutics.
  • Participation in the A.G.P. Healthcare Company Showcase highlights investor interest.
  • The fireside chat provides a platform for engaging with potential investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+2%
120-day peak, hindsight
Typical move
19.6%
average across 4 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
Autologous cell therapy
Phase 3 · Heart Failure, Systolic

Full Press Release Details

SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) --BioCardia, Inc.[Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase.
Fireside Chat Details:
• Time: 11:40 AM ET
• Date: Wednesday, May 20, 2026
Investors can register for the conference and view the fireside chathere.

About BioCardia®

BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP®autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™biotherapeutic delivery and Morph®vascular navigation product platforms. For more information visit:www.BioCardia.com.

Frequently Asked Questions

When is BioCardia's fireside chat scheduled?

The fireside chat is scheduled for May 20, 2026, at 11:40 AM ET.

How can investors register for the A.G.P. showcase?

Investors can register for the conference and view the fireside chat online.

What are BioCardia's main therapeutic platforms?

BioCardia's main platforms include CardiAMP® and CardiALLO™ for heart disease treatment.

Where is BioCardia located?

BioCardia is headquartered in Sunnyvale, California.

ShareAdd on Google
Tags: BCDA Viatris Investor Conferences Healthcare BioCardia A.G.P. Healthcare Showcase cellular therapeutics cardiovascular disease
Last updated: May 19, 2026

Biotech snapshot

Cash runway
$4M liquidity · $1M/mo burn
~7 mo
Medium dilution risk
Lead asset
Autologous cell therapyPhase 3
Heart Failure, Systolic →

Catalyst track record

+2%
best trade around BCDA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for BCDA.

See every catalyst's timing & PoA →